Clinical Trials
219 trialsA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
PIKALO-1
Eli Lilly and Company
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
OP-NEU-101
Onchilles Pharma Inc
MK-2870-001
Klus Pharma Inc.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
OrigAMI-4
Janssen Research & Development, LLC
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University School of Medicine
ELUCIDATE
Exscientia AI Limited
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
University of California, San Francisco
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
University of Colorado, Denver
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
MTAPESTRY 101
Amgen
BetaBart
Radiopharm Theranostics, Ltd
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
PNeoVCA
Mayo Clinic
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
West China Hospital
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
University of Washington
Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma
NYU Langone Health
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
A Dye for the Detection of Cancer of the Tongue and Mouth
Memorial Sloan Kettering Cancer Center
FORTITUDE-301
Amgen
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
EMITT-1
Grey Wolf Therapeutics
ODIN
OneCarbon
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Xinqiao Hospital of Chongqing
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Transgene
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center